Back to search

BIA-Brukerstyrt innovasjonsarena

SER130 - an IL-4 partial agonist for reduction of tissue damage after acute myocardial infarction

Alternative title: SER130 - en IL-4 partiell agonist for reduksjon av vevsskade etter akutt hjerteinfarkt

Awarded: NOK 1.9 mill.

Project Number:

235394

Project Period:

2014 - 2016

Funding received from:

Organisation:

Partner countries:

Our aim is to bring to the market an immunomodulatory drug being tailored for the prevention of tissue damage after myocardial infarction. The peptide SER130 (previously Ph8) - a selective interleukin-4 partial agonist - was patented by the Danish company Phlogo ApS for the treatment of immunological diseases like arthritis. After the merger between Serodus and Phlogo in 2013 Serodus changed the strategy for the compound, since arthritis is a highly competitive area with many products on the market, whereas there are no products on the market targeting the inflammatory cascade after AMI. It is known from the literature that the endogenous cytokine interleukin-4 (IL-4) has an immunomodulatory action by controlling the effects of other, immunopromoting cytokines. In fact, it is known that IL-4 and also SER130 reduce tissue necrosis factor alpha (TNFalpha). The role of TNFalpha after myocardial infarction is not clear, but literature indicates that TNFalpha has a negative role in the early phase and may have a positive role in the later phase by stimulating tissue repair. We therefore hypothesize that treatment with SER130 shortly after an infarction will reduce the negative effects of TNFalpha in the early, tissue-damaging phase. The goal of this project is to test this hypothesis, first in animal models and thereafter in a clinical study. SER130 will be the first compound in a new cardioprotective therapeutic class, which will raise significant attention in the industry internationally. SER130 is successfully following the development plan. A couple of additional pre-clinical studies will be performed before SER130 is ready to enter into a clinical trial.

Our aim is to bring to the market an immunomodulatory drug being tailored for the prevention of tissue damage after myocardial infarction. The peptide SER130 (previously Ph8) - a selective interleukin-4 partial agonist - was patented by the Danish compan y Phlogo ApS for the treatment of immunological diseases like arthritis. After the merger between Serodus and Phlogo in 2013 Serodus changed the strategy for the compound, since arthritis is a highly competitive area with many products on the market, whe reas there are no products on the market targeting the inflammatory cascade after AMI. It is known from the literature that the endogenous cytokine interleukin-4 (IL-4) has an immunomodulatory action by controlling the effects of other, immunopromoting c ytokines. In fact, it is known that IL-4 and also SER130 reduce tissue necrosis factor alpha (TNFalpha). The role of TNFalpha after myocardial infarction is not clear, but literature indicates that TNFalpha has a negative role in the early phase and may have a positive role in the later phase by stimulating tissue repair. We therefore hypothesize that treatment with SER130 shortly after an infarction will reduce the negative effects of TNFalpha in the early, tissue-damaging phase. The goal of this pro ject is to test this hypothesis, first in animal models and thereafter in a clinical study. SER130 will be the first compound in a new cardioprotective therapeutic class, which will raise significant attention in the industry internationally.

Funding scheme:

BIA-Brukerstyrt innovasjonsarena